EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Yan Zong iD, Yi Lin iD, Tuo Wei iD, Qiang Cheng iD

Advanced Materials · 2023-12 · 35 (51)

DOI: 10.1002/adma.202303261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Materials, 2023-11. Verfasst von Yan Zong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms. Die Arbeit wurde bisher 488-mal zitiert (Crossref) und nennt 215 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Clinical Medicine Plus X - Young Scholars Project, Peking University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA‐based therapies have already been approved or are in clinical trials. In this review, the focus is on mRNA‐LNP‐mediated anticancer therapy. It summarizes the main development strategies of mRNA‐LNP formulations, discusses representative therapeutic approaches in cancer, and points out current challenges and possible future directions of this research field. It is hoped that these delivered messages can help further improve the application of mRNA‐LNP technology in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNeoplasmsHumansLiposomesCOVID-19 VaccinesRNA, Messenger

Stichwörter der Autor:innen

cancer therapylipid nanoparticlesmRNA deliverymRNA therapeutics

Substanzen

Lipid NanoparticlesLiposomesCOVID-19 VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, 100871, China.
  • State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
  • Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, 100101, China.
  • Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, 100101, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.

ORCID-Profile: Yan Zong, Yi Lin, Tuo Wei, Qiang Cheng

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Clinical Medicine Plus X - Young Scholars Project, Peking University

Zitieren

APA

Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023). Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Advanced Materials, 35(51). https://doi.org/10.1002/adma.202303261

Vancouver

Zong Y, Lin Y, Wei T, Cheng Q. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Advanced Materials. 2023;35(51). doi:10.1002/adma.202303261

BibTeX
@article{Zong2023,
  author = {Zong, Yan and Lin, Yi and Wei, Tuo and Cheng, Qiang},
  title = {Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy},
  journal = {Advanced Materials},
  year = {2023},
  volume = {35},
  number = {51},
  doi = {10.1002/adma.202303261}
}
Kostenlos starten →